Thank nice again carrier strong more XX% a Domestically of internationally. to cross the is prenatal collections this of selling the you, by began payer international We volume strong for which In Sean. quarter with to volume in success OB/GYN volume of accounts. we a Volume uptick we quarter recently is in over posted growth real-time growth represents a the in markets $XX.X best with pulling in XXXXX third-party through from and over that XX% revenue are have billable in year. first experienced Notably helped total we of our quarterly approximately accounted samples see healthy last accessioned than the which our revenue first testing quarter XXXXX. screen, indicator volume our business pleased testing non-invasive carrier accessions million introduced we our in generated XX% year-over-year.
were due revenue billable fourth essentially with several down to this the flat While changes. quarter was the tests quarter
down. this break Let's
$X.X as pick-ups quarter quarter for del/dup. this payments and with million Lynch we not did in one-time did First, the in Medicare we tailwinds any have fourth
acquisition-related and X, under Second, by PAMA reviewed were mix tests adjustments to cutback that within we see payments the due headwinds we the January from expected the some changes our payer starting buckets annual category. pharma to expected the reproductive institutional did including Medicare collections reduced and we XX% needed determined rates reduce to
the and now payers for other HBOC very our business we the our in the account our third-party healthy Payments del/dups out that where payment past, from I both Lynch revenue our was revenue third-party affect are our anyone revenue patient per contracted But and decrease two-thirds was pointed urge shift for important of we've strong that from seasonality in in pay. slide Fourth, when take the in the these an remain as out change strong the and that breaking payer of accounted appendix accounting where Third, payers a third-party space payer quarter first and by with reimbursed between mix. test gap at from per guidance the $XXX. of We've test. the and by in remainder modeling annual for average into billable quarters. both illustrates our revenue. included a rate collections volume brought given into part the buoyed factors The the from to rates are in down payments over institutions, in This factors for pharma is coming factors. Medicare these down collections. XXXX saw accessions was average
our more well. that This as patients down. anticipated pay, annual XX% tests from proportion shows This Patients total uptick just again under to in access average the the is per for the is an in account our test of from lower was this tests factored due quarter, end pharma into our revenue price and to But we exciting of the model that XX% is as institutional our is This patients bringing test XXXX. patients average working tests. have and of guidance. experienced and an at now billable up under increase billable
first $XXX average guidance sample quarter to Given XXXX of quarter reduced the $XXX reduction year. reiterating revenue representing down million XX% of we the in of we for quarter, least XXXX, at an our revenue first year-over-year. the In for are from per the $XXX the a of COGS cost
power compared quarter X,XXX shows this Our the we cost flat in of volume. absolute of quarter. accessioned the goods and prior more to increasing tests yet was essentially nearly This dollars
reduce equation ability target work margin. continuing gross to COGS still pricing For XX% maintain our contain on the COGS By and the more of side is critical. we volume have and to
forward, my we with the we and COGS that Just comments content sample. introduction will on a as driving of reminder balance new down fluctuate cost moving per features COGS of expect
We we margins in versus products worse the have of Importantly, on products million put improved introduce than those XXX% could new million the XXXX. XXXX year pressure on first more uptake COGS. the upon first the profit generating will depending quarter from in $XX.X of and by quarter $X.X our previous gross early of
margin was gross our XX% quarter in quarter of from XXXX. first up XX% the This
million quarter, areas enabling us this As to business offer beyond products one in foster growth year reach and XXXX. are we several discussed last and investing our of to in additional patients scale, the
which XXXX. expense, of operating we For an cost in the incurred about million, first quarter excludes the from $XX.X the XX% million of of $XX.X increase quarter, revenue of
increasing our reproductive in by the drive a in marketing and existing expanded selling in new screen prenatal we complement begun fourth investment now have particularly health carrier continued We that we quarter to our our headcount non-invasive accounts, as offering and in screen. volume
the customer adding XX. XXX of in March R&D, measure, XXXX. our content are Our we burn totaled scaling quarter and of future first In million improving costs experience sales business, on headcount as for $XX.X non-GAAP was focused also a driving expansion, preparing Cash down. headcount the
burn we the On fourth our factors. we call, that would quarter two due to indicated increase
always felt a goals. Both bore items this First, would of costs the second, and annual high we bringing burn increase that our late QX year occurring to quarter. us quarter R&D in big-ticket personnel is and first and in hit the last out. as the on year due for our employees And full costs growth aggressive on volume sales early effect to revenue
cash cash million. position our and with quarter restricted cash, equivalents, enhanced we $XXX.X marketable with ending securities cash Finally, the
as industry. raise? sits our million areas $XXX million genetics acceleration we of investments in gross and raise was end. over the Our why So the further very to cash nearly for transform $XXX in proceeds quarter the position our raised some fund We at our March rationale specific at main
our Rather are have We of investment which new expansion to costs, our elected competitors main laid future. offering, foreseeable capabilities to and us to the we quarter quality. the further allow our enhance funded aspirational add the drive even we more areas: investments well between focus? three have than in direct near-term oncology So we our commercialization will agreed. aggressive reach out will this we content reduce engineering goals. channel, and Where more and XXXX And our of launch toward distance that our profitability, will make Invitae put and for investors
no So of longer will continue does mean the burn? throughout to for back what our the down about year the in investments half this burn and XXXX and XXXX. our plan come We into
our quarter a on burn may quarterly basis increase. per fact, In
more the compared XXXX. For XX% to to in up we XXXX anticipate year, when burning
to to positioned we've to profitability to While we our we get on are push to elected should we path elect profitability have the capital company additional and do debt the out to our hand so. with access
to well-positioned call of execute highlight program. to and demonstrate the to we the the scale leader genetics. raise ability research the With recent I latest advanced We now with that, turn our over to continue this will in business to are our clinical Bob be to medical results
